Highlights
IIA supported (ever)1 patent
About
Next Generation of RNA Therapeutics
Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation.
The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.
Identity
| Name | Eleven Therapeutics |
|---|---|
| Slug | eleven-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkMSNoKYKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Ben Yehuda Street 99, Tel Aviv-Yafo, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
respiratoryartificial-intelligencedrug-developmentmolecular-biologypharma-companiestherapeutics
Funding
| Total raised | $25.9M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}